血清CA15-3检测在胶质瘤诊断中的价值  

Diagnostic significance of serum CA15-3 to gliomas

作　　者：贺红卫[1] 刘红兵[2] 闫志勇[3] 王成伟[1] 庞琦[4] 朱树干[2] 

机构地区：[1]山东大学第二医院神经外科,山东济南250033 [2]山东大学齐鲁医院神经外科,山东济南250012 [3]德州市人民医院神经外科,山东德州253000 [4]山东省立医院神经外科,山东济南250021

出　　处：《山东大学学报（医学版）》2005年第3期257-259,共3页Journal of Shandong University:Health Sciences

摘　　要：目的:探讨肿瘤标记物CA15-3(cancer antigen 15-3)在脑胶质瘤诊断中的价值。方法:采用双抗体夹心免疫酶联法(immunoenzymometric assay,IEMA)测定190名健康人、50例脑胶质瘤患者和25例颅内良性肿瘤患者血清中的CA15-3水平,并经秩和检验行统计学分析。结果:脑胶质瘤组血清CA15-3 水平高于健康对照组(u=6.2,P<0.01),且高度恶性脑胶质瘤组CA15-3水平明显高于低度恶性脑胶质瘤组(u=75.6,P<0.01),而颅内良性肿瘤组患者血清CA15-3水平与健康对照组无统计学差异(u=51.4,P> 0.05)。结论:血清CA15-3升高可作为早期诊断脑胶质瘤的重要参考指标,可用于脑胶质瘤与颅内良性肿瘤的鉴别诊断及脑胶质瘤恶性程度的判断。Objective: To study the diagnostic significance of serum CA15-3 (cancer antigen 15-3) to gliomas. Methods: Immunoenzymometric assay (IEMA) was used to detect serum CA15-3 in 190 healthy people, 50 patients with glioma, and 25 patients with intracranial benign tumor. The data were analyzed by Wilcoxon test. Results: The serum CA15-3 level of the glioma group was significantly higher than that of the healthy control group (u=6.2, P<0.01), and the difference between malignant glioma group and lower malignant glioma group was also significant (u=75.6, P<0.01), but the difference between the intracranial benign tumor group and the healthy group was not significant (u = 51.4, P>0.05). Conclusion: The increased serum CA15-3 level may be an important marker to early diagnosis of gliomas. It is also important in differential diagnosis between gliomas and the intracranial benign tumors,and in judgement of malignant degree of gliomas.

关 键 词：肿瘤标记 生物学 CA15-3 神经胶质瘤 诊断 

分 类 号：R739.41[医药卫生—肿瘤]